非酒精性脂肪性肝病中的红细胞功能障碍：分子机制的标志物与介质
Red Blood Cell Dysfunction in Non-Alcoholic Fatty Liver Disease: Marker and Mediator of Molecular Mechanisms.
作者信息
Papadopoulos Charalampos, Tentes Ioannis, Anagnostopoulos Konstantinos
机构信息
Laboratory of Biochemistry, School of Medicine, Democritus University of Thrace, Alexandroupolis, Greece.
出版信息
Maedica (Bucur). 2020 Dec;15(4):513-516. doi: 10.26574/maedica.2020.15.4.513.
Abstract
Despite efforts to unravel the pathogenetic mechanisms of non-alcoholic fatty liver disease (NAFLD), there is still a need for approved treatments and biomarkers. Interestingly, red blood cells present alterations in their characteristics during NAFLD. The phosphatidylcholine to phosphatidylethanolamine ratio, fatty acid profile, red blood cell count and red cell distribution width reflect molecular changes that are taking place in the liver. In addition, glycosylated hemoglobin, chemokine binding and release, and phosphatidylserine exposure actively participate in NAFLD pathogenesis. In this review, we describe the neglected red blood cell dysfunction in NAFLD, with the aim to unveil potent biomarkers and therapeutic targets.
摘要
尽管人们努力揭示非酒精性脂肪性肝病（NAFLD）的发病机制，但仍需要获批的治疗方法和生物标志物。有趣的是，在NAFLD期间红细胞的特征会出现改变。磷脂酰胆碱与磷脂酰乙醇胺的比例、脂肪酸谱、红细胞计数和红细胞分布宽度反映了肝脏中正在发生的分子变化。此外，糖化血红蛋白、趋化因子的结合与释放以及磷脂酰丝氨酸的暴露都积极参与了NAFLD的发病过程。在这篇综述中，我们描述了NAFLD中被忽视的红细胞功能障碍，旨在揭示有效的生物标志物和治疗靶点。
相似文献
1
Red Blood Cell Dysfunction in Non-Alcoholic Fatty Liver Disease: Marker and Mediator of Molecular Mechanisms.
Maedica (Bucur). 2020 Dec;15(4):513-516. doi: 10.26574/maedica.2020.15.4.513.
2
High red blood cell distribution width is closely associated with nonalcoholic fatty liver disease.
Eur J Gastroenterol Hepatol. 2014 Feb;26(2):174-8. doi: 10.1097/MEG.0b013e328365c403.
3
Epigenetics in non-alcoholic fatty liver disease.
Mol Aspects Med. 2017 Apr;54:78-88. doi: 10.1016/j.mam.2016.11.008. Epub 2016 Nov 23.
4
Hyperglycemia induces key genetic and phenotypic changes in human liver epithelial HepG2 cells which parallel the Leprdb/J mouse model of non-alcoholic fatty liver disease (NAFLD).
PLoS One. 2019 Dec 5;14(12):e0225604. doi: 10.1371/journal.pone.0225604. eCollection 2019.
5
Hemoglobin combined with triglyceride and ferritin in predicting non-alcoholic fatty liver.
J Gastroenterol Hepatol. 2014;29(7):1508-14. doi: 10.1111/jgh.12580.
6
Significant decrease of saturation index in erythrocytes membrane from subjects with non-alcoholic fatty liver disease (NAFLD).
Lipids Health Dis. 2017 Aug 23;16(1):160. doi: 10.1186/s12944-017-0552-0.
7
Chemokine ligand 2 and paraoxonase-1 in non-alcoholic fatty liver disease: The search for alternative causative factors.
World J Gastroenterol. 2015 Mar 14;21(10):2875-82. doi: 10.3748/wjg.v21.i10.2875.
8
Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids.
J Nutr Biochem. 2018 Aug;58:28-36. doi: 10.1016/j.jnutbio.2018.03.025. Epub 2018 Apr 10.
9
Revisiting the metabolic syndrome and paving the way for microRNAs in non-alcoholic fatty liver disease.
FEBS J. 2014 Jun;281(11):2503-24. doi: 10.1111/febs.12806. Epub 2014 Apr 28.
10
Elevated Hemoglobin Level Is Associated With Advanced Fibrosis in Pediatric Nonalcoholic Fatty Liver Disease.
J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):150-155. doi: 10.1097/MPG.0000000000001614.
引用本文的文献
1
Innate Immunity Receptor TLR9 Drives Erythrocyte Cholesterol and Ferroprotin Accumulation in a Glutaminase-Independent Manner. Implications for Metabolic Associated Fatty Liver Disease.
Maedica (Bucur). 2025 Jun;20(2):220-227. doi: 10.26574/maedica.2025.20.2.220.
2
Eryptosis in Liver Diseases: Contribution to Anemia and Hypercoagulation.
Med Sci (Basel). 2025 Aug 12;13(3):125. doi: 10.3390/medsci13030125.
3
Significant Increase in Oxidative Stress Indices in Erythrocyte Membranes of Obese Patients with Metabolically-Associated Fatty Liver Disease.
J Pers Med. 2024 Mar 18;14(3):315. doi: 10.3390/jpm14030315.
4
Red Blood Cell-Conditioned Media from Non-Alcoholic Fatty Liver Disease Patients Contain Increased MCP1 and Induce TNF-α Release.
Rep Biochem Mol Biol. 2022 Apr;11(1):54-62. doi: 10.52547/rbmb.11.1.54.
本文引用的文献
1
Cholesterol and Phospholipid Distribution Pattern in the Erythrocyte Membrane of Patients with Hepatitis C and Severe Fibrosis, before and after Treatment with Direct Antiviral Agents: A pilot Study.
Maedica (Bucur). 2020 Jun;15(2):162-168. doi: 10.26574/maedica.2020.15.2.162.
2
Advances in non-invasive biomarkers for the diagnosis and monitoring of non-alcoholic fatty liver disease.
Metabolism. 2020 Oct;111S:154259. doi: 10.1016/j.metabol.2020.154259. Epub 2020 May 5.
3
Epidemiology of non-alcoholic and alcoholic fatty liver diseases.
Transl Gastroenterol Hepatol. 2020 Apr 5;5:16. doi: 10.21037/tgh.2019.09.08. eCollection 2020.
4
HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels.
Biosci Rep. 2020 Jan 31;40(1). doi: 10.1042/BSR20193996.
5
Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.
Int J Mol Sci. 2019 Oct 11;20(20):5037. doi: 10.3390/ijms20205037.
6
Insight into erythrocyte phospholipid molecular flux in healthy humans and in patients with acute respiratory distress syndrome.
PLoS One. 2019 Aug 27;14(8):e0221595. doi: 10.1371/journal.pone.0221595. eCollection 2019.
7
The haemoglobin glycation index is associated with nonalcoholic fatty liver disease in healthy subjects.
Clin Endocrinol (Oxf). 2019 Aug;91(2):271-277. doi: 10.1111/cen.14001. Epub 2019 May 10.
8
Changes of the Fatty Acid Profile in Erythrocyte Membranes of Patients following 6-Month Dietary Intervention Aimed at the Regression of Nonalcoholic Fatty Liver Disease (NAFLD).
Can J Gastroenterol Hepatol. 2018 Dec 4;2018:5856201. doi: 10.1155/2018/5856201. eCollection 2018.
9
Association of glycated hemoglobin with the risk of advanced fibrosis in non-alcoholic fatty liver disease patients without diabetes.
Clin Res Hepatol Gastroenterol. 2019 Feb;43(1):58-66. doi: 10.1016/j.clinre.2018.08.007. Epub 2018 Sep 28.
10
The Evolving Erythrocyte: Red Blood Cells as Modulators of Innate Immunity.
J Immunol. 2018 Sep 1;201(5):1343-1351. doi: 10.4049/jimmunol.1800565.
Zotero 插件